Lakewood-Amedex Biotherapeutics Inc. 2026年度季度报告

NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Actof 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”). In particular, statements contained in this Quarterly Report on Form 10-Q, including but not limited to, statements regarding thesufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities; our futureresults of operations and financial position, business strategy and plan prospects, or costs and objectives of management for futureacquisitions, are forward looking statements. These forward-looking statements relate to our future plans, objectives, expectations andintentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “targets,”“projects,” “contemplates,” “believes,” “seeks,” “goals,” “estimates,” “predicts,” “potential” and “continue” or similar words. Readers NOTE REGARDING COMPANY REFERENCES Throughout this Quarterly Report on Form 10-Q, “Lakewood-Amedex,” the “Company,” “we,” “us” and “our” refer to Lakewood-Amedex Biotherapeutics Inc. FORM 10-QTABLE OF CONTENTS PART I-FINANCIAL INFORMATION Item l.Condensed Unaudited Financial Statements 1Condensed Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20251Condensed Statements of Operations (Unaudited) for the three months ended March 31, 2025 and 20262Condensed Statements of Stockholders’ Equity (Deficit) (Unaudited) for the three months ended March 31, 2025 and 2026 3Condensed Statements of Cash Flows (Unaudited) for the three months ended March 31, 2026 and 20254Notes to the Condensed Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations14 PART I - FINANCIAL INFORMATION LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.Notes to Condensed Financial Statements (Unaudited) NOTE 1 – ORGANIZATION, BUSINESS OVERVIEW, AND LIQUIDITY Lakewood-Amedex Biotherapeutics Inc., a Nevada corporation (“Lakewood-Amedex” or the “Company”), headquartered inUniversity Park, Florida, was formed on July11, 2006 under the name Nu Pharmas, Inc. (“Nu Pharmas”). Lakewood-Amedex is focused on leveraging unique, pioneering science to address unmet needs in the treatment of serious infectiousdiseases, improving patient outcomes and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA,NDM-1, and many others. The Company’s product candidates consist of antimicrobials that are targeted at acute and chronicinfectious diseases, and which are delivered locally to the site of infection. As of April 2026, the Company has 68 patents and 36pending patent applications covering its products and technologies for application in major pharmaceutical markets. The Company hassuccessfully completed its first human clinical trial for its lead product, the broad-spectrum Bisphosphocin® (anti-bacterial) Nu-3 for Liquidity and Going Concern Considerations The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted inthe United States of America (“U.S. GAAP”) on a going concern basis, which contemplates the realization of assets and thesatisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments relatingto the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue asagoing concern. The Company recognized a net loss of approximately $0.9 million for the three months ended March 31, 2026. The Subsequent to March 31, 2026, on April 21, 2026, the Company completed a private offering of Series C Convertible Preferred Stockfor gross proceeds of approximately $7.5 million, resulting in net proceeds to the Company of approximately $6.8 million afterpayment of offering-related expenses. In addition, during April 2026, the Company issued approximately $0.1 million of short-term On April 23, 2026, the Company completed its listing on the Nasdaq Capital Market. In connection with the Nasdaq listing, alloutstanding convertible promissory notes with an aggregate principal balance of approximately $1.5 million, together with accruedinterest thereon, automatically converted into shares of the Company’s common stock pursuant to their terms. In addition, all While the Company believes the net proceeds received from the Series C financing, together with the elimination of certain debtobligations through the automatic conversions described above, have improved the Company’s liquidity position and will supportoperations through the fourth quarter of 2026, the Company will nevertheless require additional capital to fund operations and executeits business plan beyond that period. Accord